Key Takeaways
- Worst quarter behind, recovery expected: Revenue fell 12% YoY and EBITDA margin compressed to 4.2%, but management is "fairly confident that the worst quarter is behind us" and sees volume and value growth ahead.
- Dimer acid structurally impaired: The segment is "very marginal" because raw material carries 16.5% import duty while finished dimer carries only 7.5%, and Chinese dumping with export incentives makes price pass-through impossible.
- Export pivot hinges on policy: Tocopherol business went to zero after US tariffs; recovery of isosteric acid and dimer exports depends on US trade deal and China removing export incentives on 700 chemicals from April 1.
- No CAPEX needed for growth: With 55% capacity utilization, the target to lift exports from 9% to 50% requires zero additional CAPEX.
- What to watch next quarter: Whether Chinese export incentives are actually removed from April 1, whether the US trade deal unlocks isosteric acid orders, and whether alternative raw material trials show material impact.
Dimer Acid: The Structural Disadvantage
- Inverted duty structure: Raw material (vegetable oil) attracts 16.5% import duty while finished dimer fatty acid imports carry only 7.5%, creating a permanent margin squeeze that domestic pricing cannot offset.
- Chinese dumping: China provides export incentives to dimer manufacturers, enabling them to price below Fairchem's cost; management states that if they raise prices, customers simply import from China, and domestic players only get first preference at matching prices.
- Profitability floor: Dimer acid is "very marginal" and described as "just keeping our heads out of water," with the company choosing to supply only 40-50% of customer orders rather than accept deeply unprofitable volumes.
- Market share intact: Management asserts they have not lost market share; they were deliberately not accepting 100% of orders because margins were too low, and new entrants are described as "very marginal players."
- Potential catalyst: If dimer falls under the 700 chemical products where China removes export incentives from April 1, a 12-13% price hike from Chinese players would allow Fairchem to raise prices and ramp up production, with the additional sales price flowing directly to EBITDA.
Jariwala: "See, you need to understand, time and again we are seeing one thing, the raw material, that is vegetable oil, in India we are getting imported at 16.5% import duty, and based on that our raw material is also priced accordingly, and against that if you import dimer fatty acid, it is carrying import duty of 7.5%. So, effectively we are sufferers, because the raw material is having higher import duty, but the finished product is having lower import duty."
Export Recovery: The Policy Bet
- Tocopherol business collapsed: The segment was 100% exported to the US and has been zero for two quarters because US buyers switched to alternative suppliers after tariffs were imposed.
- Isosteric acid reopening: With the US trade deal announcement, the company has started receiving inquiries from US customers and is "pretty confident that in next six months things should be back on track."
- Export ambition: Management targets moving from 9% exports to as high as 50%, with no CAPEX required since capacity utilization is only 55%.
- Trade deal tailwinds: The US announcement of a level playing field tariff structure, plus progress toward free trade agreements with the UK and EU, provides improved visibility for export recovery across isosteric acid and dimer fatty acid.
- Tocopherol revival uncertain: Management acknowledges they will have to "revive the whole thing" if reciprocal tariffs reduce, but gave no timeline or commitment.
- Soybean oil import strategy rejected: An analyst proposed importing zero-duty US soybean oil, extracting the byproduct, and exporting duty-free; management deflected, noting that only 1% of soybean oil yields their raw material and they will not take commodity price risk on the other 99%.
Jariwala: "For every 100 kg of soybean oil, 1% of our raw material is getting generated. So, as a company, we cannot take a risk of, to get 1% material, take a risk of 99% of vegetable oil, which is a commodity, where prices go up and down every moment. So, that is something we will not dabble ourselves. It is not our core competency."
Paint Sector & Domestic Demand
- Paint offtake weakened: The paint sector witnessed lower material offtake during Q3, linked to market-share disruptions following the entry of new players, with customers demanding progressively lower prices.
- Linoleic diversification: In response to paint sector pricing pressure, the company has started exploring other applications for linoleic through process modification and quality improvement; the trend looks positive.
- Current demand stable: In January and the first week of February, demand was "above average" with no major upswing but also no downslide.
- Raw material access secure: The company sources from 80-100 refineries constituting 80-90% of India's vegetable oil processing, so availability is not a constraint.
Cost & Margin Initiatives
- Energy audit underway: The company has started a detailed energy audit and trials to reduce catalyst cost by replacing imported catalysts with domestic alternatives.
- Alternative raw materials: Work is ongoing to use different raw materials to bypass the import duty differential; material impacts are expected maybe in Q2 or Q3 FY27.
- New product development: The company is developing newer products from the current product set for different applications, though management declined to name the new product until launch.
- New product equipment timeline: Expected to go into production by Q3 FY27, with initial small capacity; major expansion will follow only after quality is satisfied and buyer approvals are received, based on experience with isosteric acid where approvals took over two to three years.
- Animal feed plant ready: The plant is complete and awaiting GMP certification before starting operations.
Capital Allocation & Capacity
- Buyback rationale: Management stated there is no pressure on cash flow; the complete volume increase over the next two years will come from current capacity (55% utilization), so the buyback was a way to increase promoters' holding.
- No CAPEX required: Management confirmed no CAPEX will be needed to achieve the 50% export target; capacity is absolutely in place.
- Western plant optionality: If an opportunity arises, the company would be ready to consider a plant in a Western country, but has not thought about it at this stage.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume and value growth | Every quarter will see volume and value growth from here | Starting Q4 FY26 |
| EBITDA margin improvement | Gradual improvement, with better numbers visible | H2 FY27 |
| Isosteric acid export recovery | US customers re-engaging; "things should be back on track" | Within six months |
| Chinese export incentive removal | If dimer falls under 700-chemical list, 12-13% price hike from Chinese players flows to EBITDA | April 1, 2026 |
| New product equipment production | Initial small capacity goes into production | Q3 FY27 |
| Alternative raw material impact | Material impacts from trials expected | Q2/Q3 FY27 |
| Animal feed plant start | Plant ready; awaiting GMP certification | Upon certification receipt |
| Export share target | Move from 9% to as high as 50% exports; no CAPEX needed | No date given |
| Previous guidance withdrawn | ₹1,000 crore revenue / 23% EBITDA margin guidance will not be reinstated | N/A |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹100 cr, -12% YoY |
| 9M FY26 revenue from operations | ₹343 cr, -18% YoY |
| EBITDA | ₹4 cr, margin 4.2% |
| 9M FY26 EBITDA | ₹14 cr, -65% YoY, margin 3.97% |
| Adjusted PAT (excl. exceptional items) | ₹60 lakhs, margin 0.6% |
| 9M FY26 PAT before exceptional items | ₹2.5 cr, margin 0.73% |
| Exceptional items | ₹88 lakhs, new Labor Code implementation |
| Volume throughput | 9,850 tonnes |
| Domestic revenue share | 91% of total revenue |
| Export revenue share | 9% of total revenue, target to reach 50% |
| Capacity utilization | ~55% |
| Raw material import duty | ~16.5% |
| Dimer acid finished product import duty | 7.5% |
| Tocopherol business | Zero for two quarters, 100% exported to US |
| Revenue decline from FY22 peak | ~₹200 cr reduction, from ~₹650 cr to ~₹450 cr (past 12 months) |
| Price decline from FY22 peak | 10% to 15% |